Quoin (QNRX) news
Recent news
Quoin Pharmaceuticals Ltd: Ex expects to report topline data in Q2 of 2027 for study of QRX003 in Netherton syndrome
AInvest Wire · 3d agoQuoin Pharmaceuticals - Aggregate net proceeds expected to fund Quoin into second half of 2029
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) has made significant regulatory and clinical progress in 2026, advancing its lead candidate, QRX003, for the treatment of Netherton Syndrome. The company has secured multiple designations across key markets, including Fast Track Designation from the U.S.…
AInvest Wire · 3d agoQuoin Pharmaceuticals - expects to complete recruitment by end of 2026, report topline data in Q2 2027
AInvest Wire · 3d agoQuoin Pharmaceuticals reports placement financing of up to $50M
AInvest Wire · 3d agoQuoin Pharmaceuticals, Inc.: Q2 loss per ADS $1.90
Quoin Pharmaceuticals, Ltd. (NASDAQ: QNRX) reported loss per ADS of $1.90 for the second quarter of 2026, according to its earnings report released on August 14, 2026. The company announced its financial results for the quarter ended June 30, 2026, ahead of the market opening, as part of a broader…
AInvest Wire · Aug 14, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.